InstalabLoading...
InstalabLoading...
Your standard cholesterol panel tells you how much cholesterol is circulating in your blood, but it cannot tell you where that cholesterol came from. Some people run high cholesterol because their liver is producing too much of it. Others run high cholesterol because their gut is absorbing too much from food. The distinction matters because the two patterns respond to different treatments, and a single total cholesterol or LDL number cannot separate them.
Lathosterol is the molecule that answers this question. It is a sterol (a fat-like compound) that your liver produces as a stepping stone on the way to making cholesterol. Because it exists only as an intermediate in that manufacturing process, measuring how much of it reaches your bloodstream gives you a direct readout of how active your liver's cholesterol production line is.
Lathosterol sits near the end of one of two pathways your liver uses to build cholesterol, called the Kandutsch-Russell pathway (one of the two main assembly lines for cholesterol in liver cells). When cholesterol production ramps up, more lathosterol leaks into the blood. When production slows down, less appears. Both the absolute concentration and the ratio of lathosterol to total cholesterol have been validated in human studies as reliable stand-in markers of whole-body cholesterol synthesis.
This is especially useful because cholesterol metabolism falls into two broad patterns. "Synthesizers" have high lathosterol and relatively low levels of plant sterols like campesterol and beta-sitosterol (which track intestinal absorption). "Absorbers" show the opposite pattern. Knowing which camp you fall into can help guide treatment: statins, which block cholesterol production, tend to work best in synthesizers, while absorption blockers like ezetimibe may be more effective in absorbers.
One of the strongest associations in the research links elevated lathosterol to metabolic dysfunction-associated steatotic liver disease, known by the abbreviation MASLD (formerly called non-alcoholic fatty liver disease, or NAFLD). People with MASLD show significantly higher plasma lathosterol and elevated ratios of lathosterol to plant sterols compared to healthy controls. Lathosterol also correlates positively with non-invasive steatosis scores, including the fatty liver index and the triglyceride-glucose index.
This suggests that excessive cholesterol manufacturing by the liver is not just a bystander in fatty liver disease but a metabolic signature of the condition. If your lathosterol is elevated alongside abnormal liver enzymes or imaging, it strengthens the case that your liver's cholesterol machinery is running too hard and contributing to fat accumulation.
In a study of 207 patients undergoing treatment for coronary artery disease (CAD), higher lathosterol identified a "cholesterol synthesis" metabolic profile that clustered with higher triglycerides and multiple oxidized cholesterol byproducts called oxysterols. These oxysterols are thought to promote plaque buildup in arteries. The finding suggests that the high-synthesis pattern carries distinct cardiovascular risks beyond what standard lipid panels reveal.
Separately, drug-induced activation of a liver receptor called PXR (pregnane X receptor), triggered by medications like the antibiotic rifampicin, was shown to raise lathosterol alongside increases in LDL cholesterol and remnant cholesterol in healthy adults. This provides a direct human demonstration that revving up cholesterol synthesis raises both the marker (lathosterol) and the artery-damaging lipids that drive heart disease.
In the AURORA trial, which followed 2,332 patients on hemodialysis (a blood-filtering treatment for kidney failure), researchers found a result that seems to contradict the pattern above. People in the highest third of lathosterol-to-cholesterol ratio had about 19% lower risk of cardiovascular death compared to those in the lowest third (hazard ratio 0.81). Meanwhile, people with the highest cholesterol absorption markers had about 36% higher cardiovascular death risk (hazard ratio 1.36).
This is not actually a contradiction. Lathosterol is a pattern indicator, not a simple "higher equals worse" risk gauge. In hemodialysis patients, who often suffer from malnutrition and chronic inflammation, higher lathosterol may signal better overall metabolic capacity rather than dangerous overproduction. What mattered more in this population was the absorption side: high cholesterol absorption, tracked by a marker called cholestanol, was the pattern that carried real danger.
A separate study of 251 patients with earlier-stage chronic kidney disease found no association between lathosterol-based markers and major cardiovascular events or death over about five years of follow-up. The takeaway is that lathosterol's prognostic value depends heavily on the population being studied, and it should be interpreted as part of a metabolic fingerprint rather than as a standalone risk number.
Adolescents and young adults with type 1 diabetes show a distinctive cholesterol metabolism profile: lathosterol is roughly 20% lower than in healthy controls, while absorption markers are higher. This flipped pattern (low synthesis, high absorption) suggests that type 1 diabetes shifts cholesterol metabolism toward the absorber pattern.
Within the diabetes group, higher lathosterol correlated with higher BMI, blood pressure, and triglycerides. So even in a population where lathosterol is generally low, higher values within that range track with worse cardiometabolic health.
Standardized clinical cutpoints for lathosterol do not yet exist. Your result is reported as an absolute concentration in mg/L, but most research interprets lathosterol as a ratio to total cholesterol (in units of micromoles per millimole of cholesterol). The ratio approach corrects for differences in total cholesterol between individuals and is considered more informative than the raw number alone.
Because this marker is best interpreted alongside companion sterols (campesterol and beta-sitosterol for absorption, desmosterol as an additional synthesis marker), a single lathosterol value in isolation provides limited clinical guidance. The most meaningful interpretation comes from comparing your synthesis markers against your absorption markers to determine your cholesterol metabolism pattern. If your lab reports a Cholesterol Balance Score or includes the full sterols panel, that composite view is far more actionable than any one number.
Your lab may report its own analytical reference range. Use that range as a rough guide, but recognize that the clinical meaning of your result depends on your full metabolic context: your BMI, liver health, lipid profile, and whether you are taking statins or other lipid-lowering medications.
Lathosterol follows a circadian rhythm (a daily cycle that peaks and dips at predictable times), rising and falling in sync with cholesterol synthesis activity. Studies in healthy adults show that both lathosterol and PCSK9 (a protein that regulates how quickly your liver clears LDL cholesterol from the blood) follow the same daily pattern. Blood drawn at different times of day can produce different lathosterol values, so consistency in draw timing matters when comparing results over time.
Fasting also markedly suppresses lathosterol. Prolonged fasting reduces circulating lathosterol in parallel with decreased PCSK9, reflecting genuine but temporary slowing of the liver's cholesterol production. If you have been fasting beyond a standard overnight fast (12 to 14 hours), your lathosterol may read artificially low.
A single lathosterol reading is a snapshot, not a verdict. Because your result is influenced by fasting status, time of day, body weight, medications, and liver health, your personal trajectory matters far more than any one reading. If you are making dietary changes, losing weight, or starting a new lipid-lowering medication, tracking lathosterol over time lets you see whether you are actually shifting your cholesterol metabolism pattern in the direction you want.
Get a baseline reading as part of a full sterols panel (including campesterol, beta-sitosterol, and desmosterol). If you are actively making changes, retest in 8 to 12 weeks, which is the timeframe over which diet-induced weight loss and plant stanol interventions have shown measurable shifts. After that, annual monitoring is reasonable for most people. Always try to draw blood at the same time of day and after the same fasting duration for the most comparable results.
If your lathosterol is elevated relative to your lab's reference range, the first step is to look at the full picture. Check your companion absorption markers (campesterol and beta-sitosterol). If lathosterol is high and absorption markers are low, you are a "synthesizer," and therapies that block cholesterol production (like statins) are likely to be your most effective tool. If both synthesis and absorption markers are elevated, the picture is more complex and may warrant investigation for underlying metabolic conditions like fatty liver disease.
Pair your sterols result with standard liver function tests (ALT, AST, GGT) and metabolic markers (triglycerides, fasting insulin, HbA1c). An elevated lathosterol alongside abnormal liver enzymes and high triglycerides is a strong signal to investigate for MASLD with imaging or further workup. A lipidologist (a doctor specializing in cholesterol disorders) or hepatologist (a liver specialist) can help interpret the full pattern.
If your lathosterol is low, consider whether you are in an absorber pattern, which carries its own set of risks. High absorption markers with low synthesis markers may mean ezetimibe or dietary plant sterol/stanol strategies are more appropriate than statins for managing your cholesterol. Low lathosterol also appears in type 1 diabetes and in advanced liver disease, so context matters.
Evidence-backed interventions that affect your Lathosterol level
Lathosterol is best interpreted alongside these tests.